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Objective: Previous research has revealed a relationship of depressive symptoms and 
hopelessness with cardiovascular diseases (CVDs) which are associated with elevated levels of 
interleukin-6 (IL-6).  The objective of this study was to explore whether depressive symptoms 
and hopelessness are independent predictors of IL-6 levels.  Method: Hopelessness, depressive 
symptoms, and IL-6 were measured in 45 Swedish adults (26 women and 19 men; age range: 31-
65 years).  Two separated linear regressions were conducted with hopelessness and depressive 
symptoms serving as individual predictors of IL-6.  Another regression analysis examined 
whether the two predictors predict IL-6 when controlling for each other.  The regression 
coefficients of the models with one predictor and with both predictors were compared.  Results: 
As predicted, after adjusting for age, BMI, illness, smoking, and gender, more depressive 
symptoms and more hopelessness predicted higher IL-6 levels in independent regressions.  When 
controlling for each other, hopelessness, but not depressive symptoms, predicted IL-6 levels.  
Finally, when controlling for hopelessness, the regression between depressive symptoms and IL-
6 level was significantly reduced; however, there was no significant change in the regression 
between hopelessness and IL-6 level when controlling for depressive symptoms.  Conclusions: 
Thus, these results suggest that depressive symptoms and hopelessness are not independent 
predictors of IL-6 levels.  Future research should explore the interplay of hopelessness and 
depressive symptoms on other risk factors of CVDs. 
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Introduction 
The Global Burden of Disease study launched by the World Health Organization predicts 
cancer and cardiovascular disorders (CVD) to be one of the leading causes of death worldwide 
by 2030 [1].  In high-income countries, an estimated 3.17 million people died from CVD in 
2001, representing more than 40% of deaths [2].  Presently, psychosocial factors in general, and 
depressive symptoms in particular, are prospectively associated with incidents of CVD [for a 
meta-analysis see 3].  As such, the pro-inflammatory cytokine IL-6 is known as the major 
regulator of acute phase protein synthesis [4] and stimulator of the hypothalamic-pituitary-
adrenal (HPA) axis during inflammatory stress [5] and it is also related to a higher risk of CVD 
[6].  Thus, IL-6 may play a role in the mechanisms linking psychosocial stressors to disease. 
Recent literature has emphasized identifying which specific aspects of depression are 
strong predictors of CVDs, and their corresponding biological risk factors.  Hopelessness seems 
to be characterized as such, a “toxic” symptom of depression.  Hopelessness - the negative view 
of the future - often occurs with severe episodes of depression [7].  Nevertheless, hopelessness is 
not recognized as a symptom of depression in the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV-TR) [8] and two prominent models explaining the development and 
maintenance of depression view hopelessness as a risk factor and not as a symptom of depression 
[9; 10].  Thus, hopelessness may be distinct from depression in its associations with biological 
risk factors of CVD, a hypothesis supported by multiple studies.  For example, in a cross-
sectional study [11], hopelessness was a significant predictor of mean and maximum carotid 
artery intimal-medial thickening (IMT) whereas depressive symptoms marginally predicted IMT.  
After entering both variables in the same model, hopelessness but not depressive symptoms 
remained a predictor of IMT.  Similarly a 18-year longitudinal study with men without previous 
CVD revealed that hopelessness and depressive symptoms predicted myocardial infaction (MI) 
incidents when not controlling for each other.  However, when controlling for each other, 
depressive symptoms no longer significantly influenced the risk of MI while hopelessness 
continued to predict MI incidents [12].  Other publications demonstrated that hopelessness 
predicts hypertension [13] and carotid atherosclerosis [15] even after controlling for depressive 
symptoms.  Given such findings and the significance of IL-6, understanding whether 
hopelessness and depressive symptoms are independent predictors of IL-6 levels is important to 
address. 
Based on theoretical considerations [9; 10] and empirical findings [e.g., 11-14], it can be 
predicted that hopelessness and depressive symptoms are independently associated with IL-6 but 
that the association between depressive symptoms and IL-6 will no longer be significant when 
controlling for hopelessness; whereas, the association between hopelessness and IL-6 will not be 
influenced by depressive symptoms. 
Method 
Participants 
Data was collected as part of a broader survey of health that is discussed in detail in prior 
studies [15].  This study consisted of 45 residents (26 women and 19 men), ranging from age 31 
to 65 years (mean age = 48.07 years, SD = 8.54), residing in the county of Östergötland in 
Sweden.  The participants reported no chronic conditions that could affect their immune system; 
however, other health concerns were reported by 19 of the participants, including hypertension, 
fibromyalgia, musculoskeletal pain, chronic lunch disease, psoriasis, allergy, and impaired 
vision. 
Materials 
Major Depression Inventory (MDI; 16; 17).  The MDI was administered to evaluate 
symptoms of depression in participants over the past two weeks.  The MDI is comprised of ten 
items that reflect the DSM-IV criteria, with the exception that self-esteem and guilt are measured 
with two items on the MDI rather than one item on the DSM-IV.  Participants utilized a six-point 
Likert scale to respond to each item, with a range of 0 (at no time) to 5 (all of the time).  Item 
responses were summed to obtain an overall depression score, with a potential range between 0 
and 50.  The MDI correlates reportedly with the Hamilton Depression Scale [17].  Cronbach’s 
alpha was .0.94. 
Hopelessness Scale [18].  Hopelessness was assessed utilizing two items: “I feel that it is 
impossible to reach the goals I would like to strive for” and “The future seems to me to be 
hopeless, and I can't believe that things are changing for the better.”  Responses by participants 
were recorded on a five-point Likert scale ranging from 0 (absolutely agree) to 4 (absolutely 
disagree), and the items were reverse-scored and summed to produce a hopelessness score.  The 
correlation between the two items was r = 0.77.  Prior research has utilized these items to assess 
hopelessness [e.g., 15]. 
 Demographic Variables.  Participants reported demographic information, including age, 
gender, smoking, BMI (mean = 25.12, SD = 4.27), and illness.  Smoking was coded into one of 
six groups: never (33.3%, n = 15), stopped smoking (31.1%, n = 14), sometimes (11.1%, n = 5), 
less than 10 cigarettes per day (13.3%, n = 6), 10 to 20 cigarettes per day (11.1%, n = 5), or more 
than 20 cigarettes per day (0%, n = 0).  Further, Illness was coded as a dichotomous variable and 
either did (42.2%, n = 19) or did not (57.8%, n = 26) occur for each participant [cf. 15]. 
Procedure 
Prior to the collection of blood samples and responses on survey items, the procedure and 
aims of the study were explained to potential participants and they provided written consent, as 
approved by the university IRB.  Participants did not take any medication during or immediately 
prior to blood collection; further, if participants had some type of illness two weeks prior to the 
blood sample collection, they were requested to return after recovery.  Venous blood samples 
were drawn between 8:00 and 9:00 in the morning. The blood was centrifuged within one hour 
and sera were frozen at -70 °C. 
 Procedure for IL-6 
 IL-6 [15] was measured in duplicate with a chemiluminescence-based sandwich enzyme 
immunoassay technique (QuantiGlo Human IL-6 Immunoassay Kit, R&D Systems Europe, 
Abingdon, UK).  The inter- and intra-assay coefficients of variation (CV) for plasma were 9.2% 
and 2.8%, respectively.  The standard curve of IL-6 was linear between 0.15 and 3000 pg/mL 
and the sensitivity of the assay was 0.15 pg/mL. 
Data Analysis 
To evaluate the hypotheses, three linear regression models and two paired t-tests were 
conducted.  More specifically, three regression models were calculated with IL-6 levels as the 
dependent variable: one model with depressive symptoms as the predictor, one model with 
hopelessness as the predictor, and one model with both depressive symptoms and hopelessness 
as predictors.  All regression models were adjusted for the effects of age, BMI, illness (e.g., 
hypertension, psoriasis), smoking, and gender.  Finally, paired t-tests were conducted to evaluate 
the regression coefficients from the models with one predictor (depressive symptoms or 
hopelessness) to the model with both predictors (depressive symptoms and hopelessness). 
The hypotheses would be classified as correct when a) hopelessness and depressive 
symptoms both significantly predict IL-6 levels when not controlling for each other; b) the 
regression coefficient of depressive symptoms, but not hopelessness, is significantly reduced in 
the model with both predictors (hopelessness and depressive symptoms) compared to the models 
with one predictor (hopelessness or depressive symptoms). 
Results 
The relationship between depressive symptoms and hopelessness was positively 
associated at r = .34 (p < .001).  The regression model with depressive symptoms (mean = 7.67, 
SD = 8.51) predicting IL-6 levels (mean = .12, SD = .40) revealed that greater depression 
symptomatology was significantly associated with higher IL-6 levels (p = .027; Table 1).  
Similarly, the regression model with hopelessness (mean = 2.11, SD = 2.17) predicting IL-6 
levels revealed that greater hopelessness was significantly associated with higher IL-6 levels (p = 
.002; Table 1).  The final regression model included both depressive symptoms and hopelessness 
as predictors of IL-6 levels, and hopelessness (p = .022) remained significantly associated with 
IL-6; whereas, depressive symptoms was no longer associated with IL-6 levels (p = .577; Table 
1). 
 
- Insert Table 1 here - 
 
Further, regression coefficients from the models with one predictor (depressive 
symptoms or hopelessness) were compared to the corresponding predictors’ regression 
coefficients in the final model (depressive symptoms and hopelessness) using paired t-tests.  
Results revealed that there was a significant reduction in the regression coefficient of depressive 
symptoms (t(44) =  4.28; p < .001) but not in the regression coefficient for hopelessness (t(44) = 
1.17; p = .248).  
Discussion 
Based on theoretical considerations [9; 10] and empirical findings [11-14], the aim of the 
study was to test whether depressive symptoms and hopelessness were independent predictors of 
IL-6 levels.  Summarized, the results were consistent with the hypothesis that hopelessness but 
not depressive symptoms was an independent predictor of IL-6 levels.  The relevance of these 
results is important given that IL-6 has been consistently linked to clinical depression when not 
controlling for hopelessness [19] and that IL-6 may play a role in linking depressive symptoms 
to CVD.  Thus, if replicated, this finding may explain the bidirectional association between 
CVDs and depression.   
Attempts have been made to reduce IL-6 or CVDs reoccurences by reducing depressive 
symptoms in patients with CVD.  However, a recent meta-analysis of studies researching the 
effects of pharmacotherapeutic interventions to reduce depressive symptoms in patients with 
CVD did not improve the readmission and the mortality rate although medication decreased 
depression symptoms [20].  Further, not all pharmaco- and psychotherapeutic interventions 
effective in treating depressive symptoms impact hopelessness equally well [for a review see 21].  
Thus, research combined with the findings of this study might help explaining the results of the 
meta-analysis.  Future studies of therapeutic approaches attempting to reduce CVDs should focus 
on approaches that demonstrated in other populations to be successful in reducing hopelessness 
(e.g., Acceptance and Commitment Therapy, Problem-Solving Treatment; 22, 23) 
Although theoretical considerations [9; 10] allow for the conclusion that hopelessness is a 
risk factor of both depressive symptoms and elevated IL-6 levels causing the impression of an 
association between depressive symptoms and IL-6, it was not possible to test this hypothesis in 
this study because depressive symptoms and hopelessness were measured at the same time point.  
To be able to test the direction of such associations, a study with three equal waves of data 
collection is needed [24].  This seems especially important because although hopelessness is not 
a symptom in the DSM-IV-TR [8], some researchers conceptualize hopelessness as a symptom 
rather than a risk factor of depression [e.g., 25].  Thus, an alternative interpretation of our 
findings might be that hopelessness is simply the “active factor” that connects depression to IL-6 
levels.  Further, possible explanations for our findings include but are not limited to (a) 
hopelessness may mediate the effect of depression on IL-6 levels, (b) a covariate may control for 
more variability in one predictor than in the other and thereby allow one predictor (e.g., 
hopelessness) to achieve greater predictive power relative to the other predictor (e.g., depressive 
symptoms), (c) an omitted covariate (e.g., socio-economic status) is undercontrolled with respect 
to one predictor (e.g., hopelessness) but not  the other (e.g., depressive symptoms), (d) IL-6 
causes hopelessness, or (e) a common factor (e.g., disease, obesity) causes both elevated IL-6 
and hopelessness levels. 
Thus, the findings call not only for replication but also for further explorations of the 
interplay of hopelessness, depressive symptoms, and other variables on hypertension, 
atherosclerosis, and heart rate variability as biological risk factors of CVDs.  Although previous 
research has studied the impact of some risk factors of depressive symptoms, such as childhood 
abuse [26], many other risk factors of depressive symptoms have not been examined.  
Considering that both above mentioned psychological models of depression [9; 10] propose 
multiple cognitive risk factors of depression (i.e., dysfunctional attitudes, pessimistic cognitive 
style), studies including multiple psychosocial factors seem fruitful.  Such studies will contribute 
to further integration of psychological and biological models into a bio-psycho-social model of 
heart health. 
Beyond the cross-sectional design which precludes drawing of causal conclusions, the 
use of one format (e.g., self-report questionnaires), compared to a multi-method approach, to 
measure hopelessness and depressive symptoms is a limitation of the reported study.  
Additionally, the 2-item hopelessness scale that was used in this study has not been compared 
with other hopelessness scales.  Nevertheless, it has been well-validated and in previous studies 
it has predicted various cardiovascular and metabolic outcomes [e.g., 15]. 
Summarized, the present study supports the hypothesis that hopelessness but not 
depressive symptoms is an independent predictor of IL-6 levels.  Because this study was cross-
sectional and many other risk factors of depressive symptoms have not been examined, future 
research should explore the relationships between risk factors of depression, depressive 
symptoms, and IL-6 with other biological risk factors of CVDs and CVDs. 
 
Acknowledgments 
We thank the Swedish National Board of Research, The County Council of Östergötland, and 
Linköping University. 
References 
[1] Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 
2030. PLoS Med 2006;3:2011–2030. 
[2] Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global Burden of Disease and 
Risk Factors. Washington DC: World Bank & Oxford University Press, 2006. 
 [3] Leung YW, Flora DB, Gravely S, Irvine J, Carney RM, Grace SL. The impact of premorbid 
and postmorbid depression onset on mortality and cardiac morbidity among patients with 
coronary heart disease: meta-analysis. Psychosom Med 2012;74:786-801. 
[4] Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase 
response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. 
Hepatology 1990;12:1179–1186. 
[5] Papanicolaou D, Wilder R, Manolagas S, Chrousos G. The pathophysiology of interleukin-6 
in human disease. Ann Intern Med 1998;128:127–137. 
[6] Mastorakos G, Chrousos G, Weber J. Recombinant interleukin-6 activates the hypothalamic–
pituitary–adrenal axis in humans. J. Clin Endocrinol Metab 1993;77:1690–1694. [7] Brown 
G, Harris T. Social Origins of Depression. London, England: Tavistock, 1978. 
[8] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 
Fourth Edition Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric 
Association, 2000. 
[9] Abramson LY, Metalsky GI, Alloy LB. Hopelessness depression: A theory-based subtype of 
depression. Psychol Rev 1989;96:358-372. 
[10] Beck AT. Cognitive therapy and the emotional disorders. New York: International 
University Press, 1976. 
[11] Whipple MO, Lewis TT, Sutton-Tyrrell K, Matthews KA, Barinas-Mitchell E, Powell LH, 
Everson-Rose SA. Hopelessness, depressive symptoms, and carotid atherosclerosis in 
women: The Study of Women’s Health Across the Nation (SWAN) Heart Study. Stroke 
2009;40:3166–3172. 
[12] Pössel P, Mitchell AM, Ronkainen K, Kaplan GA, Kauhanen J, Valtonen M. Does 
Depression Predict the Incidence of Myocardial Infarction Independent of Hopelessness? J 
Health Psychol submitted; JHP-13-0086. 
[13] Everson SA, Kaplan GA, Goldberg DE, Salonen JT. Hypertension incidence is predicted by 
high levels of hopelessness in Finnish men. Hypertens 2000;35:561-567. 
[14] Pollitt RA, Daniel M, Kaufman JS. Mediation and modification of the association between 
hopelessness, hostility, and progression of carotid atherosclerosis. Journal of Behav Med 
2005;28:53-64.  
[15] Sjögren E, Leanderson P, Kristenson M, Ernerudh J. Interleukin-6 levels in relation to 
psychosocial factors: Studies on serum, saliva, and in vitro production by blood 
mononuclear cells. Brain Behav Immun 2006;20:270-278. 
[16] Bech P. Quality of life instruments in depression. Eur Psychiatry 1997;12:194-198. 
[17] Olsen LR, Jensen DV, Noerholm V, Martiny K, Bech P. The internal and external validity 
of the major depression inventory in measuring severity of depressive states. Psychol Med 
2003;33:351-356. 
[18] Everson SA, Goldberg DE, Kaplan GA, Cohen RD, Pukkala E, Tuomilehto J, Salonen, JT. 
Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. 
Psychosom Med 1996;58:113-121. 
 [19] Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK,Lanctot KL. A meta-
analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-457. 
[20] Pizzi C, Rutjes AWS, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of 
Selective Serotonin Reuptake Inhibitors in patients with depression and coronary heart 
disease. Am J Cardiol 2011;107:972-979. 
[21] Pössel P, Hautzinger M. Effekte pharmakologischer und psychotherapeutischer 
Interventionen auf Depressionen bei Kindern und Jugendlichen. [Effects of pharmaco- 
and psychotherapeutic interventions of depression in children and adolescents.] Z Kinder 
Jugendpsychiatr 2006;34:243-255. 
[22] Morton J, Snowdon S, Gopold M, Guymer E. Acceptance and commitment therapy group 
treatment for symptoms of borderline personality disorder: a public sector pilot study. 
Cog Behav Practice 2012;19:527-544. 
[23] Townsend E, Hawton K, Altman DG, Arensman E, Gunnell D, Hazell P, House A, van 
Heeringen K. The efficacy of problem-solving treatment after deliverate self-harm: meta-
analysis of randomized controlled trials with respect to depression, hopelessness and 
improvement in problems. Psychol Med 2001;31:979-988. 
[24] Cole DA, Maxwell SE. Testing mediational models with longitudinal data: Questions and 
tips in the use of structural equation modeling. J Abnorm Psychol 2003;112:558–577. 
[25] Do DP, Down JB, Ranjit N, House JS, Kaplan GA. Hopelessness, depression, and early 
markers of endothelial dysfunction in U.S. adults. Psychosom Med 2010;72:613-619. 
[26] Fuller-Thomson E, Brennenstuhl S, Frank J. The association between childhood physical 
abuse and heart disease in adulthood: Findings from a representative community sample. 
Child Abuse Negl 2010;34:689-698.  
Table 1 





Depressive symptoms & 
Hopelessness-IL-6 
 β β β 
   Depressive 
     symptoms 
0.34* --- 0.10 
   Hopelessness --- 0.48** 0.42* 
Covariates    
   Age 0.54** 0.35* 0.37* 
   BMI  -0.36* -0.17 -0.22 
   Illness -0.22 -0.17 -0.17 
   Smoking -0.04 0.04 0.02 
   Gender 0.11 -0.10 -0.08 
Total R2 0.37** 0.45** 0.45** 
Note. *p < .05; **p < .01 
